310 related articles for article (PubMed ID: 24328412)
1. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.
Cronin-Fenton DP; Damkier P; Lash TL
Future Oncol; 2014 Jan; 10(1):107-22. PubMed ID: 24328412
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.
Cronin-Fenton DP; Damkier P
Adv Pharmacol; 2018; 83():65-91. PubMed ID: 29801584
[TBL] [Abstract][Full Text] [Related]
3. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.
Cronin-Fenton DP; Lash TL
Expert Rev Clin Pharmacol; 2011 May; 4(3):363-77. PubMed ID: 21709817
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
Briest S; Stearns V
Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
6. Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?
Pritchard KI
Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S18. PubMed ID: 21172080
[No Abstract] [Full Text] [Related]
7. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
8. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
Zembutsu H; Sasa M; Kiyotani K; Mushiroda T; Nakamura Y
Expert Rev Anticancer Ther; 2011 Feb; 11(2):185-93. PubMed ID: 21342038
[TBL] [Abstract][Full Text] [Related]
9. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
Desmarais JE; Looper KJ
J Clin Psychiatry; 2009 Dec; 70(12):1688-97. PubMed ID: 20141708
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Singh MS; Francis PA; Michael M
Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.
de Souza JA; Olopade OI
Semin Oncol; 2011 Apr; 38(2):263-73. PubMed ID: 21421116
[TBL] [Abstract][Full Text] [Related]
13. Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.
Cronin-Fenton D; Lash TL; Sørensen HT
Future Oncol; 2010 Jun; 6(6):877-80. PubMed ID: 20528223
[No Abstract] [Full Text] [Related]
14. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen, antidepressants, and CYP2D6: the conundrum continues.
Holzman D
J Natl Cancer Inst; 2009 Oct; 101(20):1370-1. PubMed ID: 19797723
[No Abstract] [Full Text] [Related]
17. Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling.
Young D
Am J Health Syst Pharm; 2006 Dec; 63(23):2286, 2296. PubMed ID: 17105997
[No Abstract] [Full Text] [Related]
18. Tamoxifen and CYP2D6: a contradiction of data.
Hertz DL; McLeod HL; Irvin WJ
Oncologist; 2012; 17(5):620-30. PubMed ID: 22531359
[TBL] [Abstract][Full Text] [Related]
19. Do antidepressants reduce the effectiveness of tamoxifen?
Breitbart W
Psychooncology; 2011 Jan; 20(1):1-4. PubMed ID: 21182159
[No Abstract] [Full Text] [Related]
20. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]